Regencell Bioscience Holdings (Regencell Bioscience Holdings) ROCE %

: -41.27% (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Regencell Bioscience Holdings's annualized ROCE % for the quarter that ended in Jun. 2023 was -41.27%.

Regencell Bioscience Holdings ROCE % Historical Data

The historical data trend for Regencell Bioscience Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

-113.34

-42.60

Regencell Bioscience Holdings Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
ROCE %					-	-85.77	-41.13	-41.59	-41.27

Regencell Bioscience Holdings ROCE % Calculation

Regencell Bioscience Holdings's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-6.274	/	( ( (18.019 - 0.578)	+	(12.622 - 0.607) )	/ 2 )
	=	-6.274	/	( (17.441	+	12.015)	/ 2 )
	=	-6.274	/	14.728
	=	-42.60 %

Regencell Bioscience Holdings's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	-5.688	/	( ( (15.548 - 0)	+	(12.622 - 0.607) )	/ 2 )
	=	-5.688	/	( ( 15.548	+	12.015 )	/ 2 )
	=	-5.688	/	13.7815
	=	-41.27 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

Regencell Bioscience Holdings (NAS:RGC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Regencell Bioscience Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG

Website

https://www.regencellbioscience.com

Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.